Hypertension, endothelium, and cardiovascular risk factors

Article Abstract:

The endothelium is the layer of cells forming the inner lining of the blood vessels. It plays a very important role in the control of cardiovascular function. A variety of substances released from the endothelium under different conditions affect the responses to vasodilators such as prostacyclin, and to vasoconstrictors such as catecholamines, bradykinin, serotonin, and angiotensin II. (Vasodilators cause blood vessels to relax and vasoconstrictors cause them to contract.) One endothelial product that appears to be important in the regulation of blood pressure, among other functions, is endothelium-derived relaxing factor (EDRF). Another substance released by the endothelium is an as-yet unidentified factor that causes blood vessel relaxation by activating the transport of electrically charged ions across the membrane of the smooth muscle of the vascular system. The actions of these substances are dependent on the presence of an intact endothelium, and when this portion of the vasculature is damaged, disturbances in blood pressure regulation are often exacerbated. Several disease conditions can cause injury to the endothelium, including hypertension (high blood pressure), diabetes, and atherosclerosis (the formation of fatty plaque deposits on the inner surface of blood vessels). The endothelial damage caused by these various conditions is very similar, and may reflect a common mechanism. When these risk factors co-exist, a synergistic effect is often observed, and the degree of vascular injury is greater than the sum of the individual components. Arrest, prevention, and reversal of endothelial damage will be a major therapeutic focus in the future. (Consumer Summary produced by Reliance Medical Information, Inc.)

Cardiovascular diseases, Risk factors, Physiological aspects, Vascular endothelium, Endothelium-derived relaxing factors

---

Concerns about diabetic nephropathy in the treatment of diabetic hypertensive patients

Article Abstract:

Kidney failure is a long-term consequence of diabetes mellitus. It occurs in 40 percent of the patients with insulin-dependent-diabetes mellitus (IDDM) and less often in non-insulin-dependent diabetes mellitus (NIDDM). Diabetic nephropathy is evidenced by protein in the urine, high blood pressure and decreased glomerular filtration rate (GFR), the ability of the kidney to filter the blood. Diabetic nephropathy seems to occur in families, suggesting a genetic predisposition to kidney damage resulting from the physiological effect of the diabetes disease process itself. In addition, the altered chemical composition of kidney structures from the diabetic disease process causes changes in the kidney which contribute to the development of high blood pressure. Identification of individuals at risk because of a genetic predisposition to nephropathy may help prevent end stage kidney failure. Diabetic nephropathy begins with small but detectable changes. Subtle abnormal protein secretions in the urine and small increases in blood pressure may indicate the beginnings of kidney damage. Therefore, controlling high blood pressure can prevent the progression of damaging nephropathy. Since high blood pressure is directly associated with the development and progression of nephropathy, its treatment in the earliest stages is essential in diabetics, particularly insulin-dependent diabetics. Angiotensin-converting-enzyme inhibitors, a type of blood pressure lowering agent, offer the most protection from kidney injury caused by high blood pressure and diabetes.

Care and treatment, Diabetics, Diabetic nephropathies

---

Myocardial disease in hypertensive-diabetic patients

Article Abstract:

Cardiomyopathy is a disease of the heart muscle. Atherosclerosis, the build-up of plaque inside of blood vessels, can cause a compromised blood supply to the heart muscle resulting in cardiomyopathy. However, patients with diabetes mellitus often have high blood pressure and can develop cardiomyopathy that is not associated with atherosclerosis. It is difficult to ascertain whether diabetes and high blood pressure are independently involved in the cause of cardiomyopathy. The combined effect of diabetes and high blood pressure produces cardiomyopathy that is more severe than when the condition is found in either diabetes or hypertension alone. With this information in mind, drugs used to control high blood pressure should be selected carefully as not to alter the glucose control or worsen already compromised heart functioning in diabetic patients. Calcium antagonists and angiotensin-converting enzyme inhibitors are two types of blood pressure-lowering drugs which offer the best therapy for diabetic patients. In addition, weight loss improves diabetes and high blood pressure as well as reducing the size of the enlarged ventricle of the heart, which improves heart functioning.

Drug therapy, Cardiomyopathy, Myocardial diseases

Similar abstracts:

• Abstracts: Renovascular hypertension. Peripheral arterial disease of the lower extremity. Aortic dissection
• Abstracts: Pathophysiology of vascular disease in diabetes: effects of gliclazide. Oral treatment of diabetes mellitus: the contribution of gliclazide
• Abstracts: Challenges and opportunities for personal selling. Cultivating loyal patients. From fried rice to sushi: to market an integrated delivery system, throw out the old menu
• Abstracts: New Therapies Emerge for Metastatic Colon Cancer. Cardiovascular Disease: Four New Therapies. New Products Could Double The Dermatology Market by 2007
• Abstracts: Cardiovascular gene therapy: more activity, more diseases, more optimism. Molecular medicine: we will see breakthroughs this decade

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.